Elicio Therapeutics (ELTX) Total Liabilities (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Total Liabilities came in at $24.1 million in Q1 2026, up 25.4% YoY from $19.2 million in Q1 2025, and little changed on a QoQ basis from $24.2 million in Q4 2025.
Elicio Therapeutics (ELTX) Total Liabilities (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Total Liabilities data on file, last reported at $24.1 million in Q1 2026.
- Quarterly Total Liabilities rose 25.4% year-over-year to $24.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.1 million (up 25.4% YoY) and the FY2025 annual result came in at $24.2 million, down 38.65% from the prior year.
- Total Liabilities held at $24.1 million in Q1 2026, from $24.2 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $57.4 million in Q3 2024 to a low of $2.1 million in Q1 2023.
- A 5-year average of $20.8 million and a median of $17.7 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities tumbled 85.05% — and 2024, when it soared 833.37%.
- Tracing ELTX's Total Liabilities over 5 years: stood at $13.7 million in 2022, then climbed by 14.72% to $15.8 million in 2023, then jumped by 150.36% to $39.5 million in 2024, then slumped by 38.65% to $24.2 million in 2025, then decreased by 0.41% to $24.1 million in 2026.
- The last three Total Liabilities figures came in at $24.1 million (Q1 2026), $24.2 million (Q4 2025), and $24.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 23.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.39 Mn |
| Mar 31, 2026 | 24.13 Mn |
| Dec 31, 2025 | 24.23 Mn |
| Sep 30, 2025 | 24.47 Mn |
| Jun 30, 2025 | 27.69 Mn |
| Mar 31, 2025 | 19.24 Mn |
| Dec 31, 2024 | 39.49 Mn |
| Sep 30, 2024 | 57.37 Mn |
| Jun 30, 2024 | 17.40 Mn |
| Mar 31, 2024 | 19.61 Mn |
| Dec 31, 2023 | 15.77 Mn |
| Sep 30, 2023 | 17.70 Mn |
| Jun 30, 2023 | 14.06 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 13.75 Mn |
| Sep 30, 2022 | 11.11 Mn |
| Jun 30, 2022 | 11.05 Mn |
| Mar 31, 2022 | 14.06 Mn |
| Dec 31, 2021 | 15.01 Mn |
| Sep 30, 2021 | 45.43 Mn |